Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-26-000097
Filing Date
2026-08-06
Accepted
2026-08-06 16:08:18
Documents
78
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20260630.htm   iXBRL 10-Q 1122176
2 EX-10.1 exhibit101assetpurchaseagr.htm EX-10.1 184436
3 EX-31.1 exhibit311q22026.htm EX-31.1 9933
4 EX-31.2 exhibit312q22026.htm EX-31.2 9953
5 EX-32.1 exhibit321q22026.htm EX-32.1 5630
6 EX-32.2 exhibit322q22026.htm EX-32.2 5759
  Complete submission text file 0001714899-26-000097.txt   6849176

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20260630.xsd EX-101.SCH 47971
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20260630_cal.xml EX-101.CAL 67501
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20260630_def.xml EX-101.DEF 198668
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20260630_lab.xml EX-101.LAB 599607
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20260630_pre.xml EX-101.PRE 417999
82 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20260630_htm.xml XML 906379
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 261248985
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)